A radiochemical procedure is described for specific determination of pteroylglutamate in serum and urine. This method depends on denaturation of methyltetrahydrofolate with peroxide and measurement of the residual folate by a ligand-binding radioassay. The binding determinant for the radioassay is a folate-binding protein, partially purified from chronic myelogenous leukemia cells, that has low affinity for the reduced folates and thus will preferentially measure residual pteroylglutamate rather than any nondenatured residual methyltetrahydrofolate. We used this assay to measure the clearance from plasma and the urinary excretion of pteroylglutamate and a small fraction of serum folate that is stable to this oxidation procedure. The plasma clearance after intravenous injection is characterized by an initial rapid distribution phase followed by a second, slower metabolic phase; after about 2 h all of the administered pteroylglutamate has been cleared from the blood. The peak concentration of total folate in serum 1-2 mm after administration of pteroylglutamate exceeded the sum of the endogenous stable and baseline serum folate, indicating that a reduced labile folate was released from the liver and perhaps from other tissues. This reduced folate had a slower metabolic clearance rate and was excreted to some extent in urine. Only 2.3 and 7.9% of the pteroylglutamate administered to two normal subjects was excreted as stable folate. (3,4) , butbothoftheseprocedures will also measure pteroylglutamic acid (PGA). Accordingly, studies to determine the specific plasma clearance and metabolic turnover of PGA have required the application of microbiological assays with use of L. casei, which measures methylFH4 and PGA, and Streptococcus faecalis, which measures PGA but not methylFH4 (5). #{149} To circumvent the problem of using two tedious microbiological assays in order selectively to measure the plasma clearance and metabolic turnover of PGA, we have developed a procedure to selectively oxidize endogenous methylFH4 in
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Extraction of Serum
To measure the PGA (and endogenous, similarly stable folate) in serum, the serum must be extracted by a procedure that will (a) denature the endogenous methylFH4, (b) dena- 
Radioassay Procedures
We measured the total folate in the serum before extraction according to the sequential noncompetitive radioassay we previously described (4), using the folate binder prepared from milk and methylFH4 standards.
To measure the stable folate remaining in the extracts, we used a competitive system with the folate binder partially purified from CML cells (10) and PGA for the standard curve. This minimizes the measurement of any residual methylFH4 because the affinity of this CML folate binder for reduced folates is much lower than for nonreduced forms of folate (10) . Table 2 summarizes the analytical recovery of unlabeled PGA and methylFH4 added to normal serum and then subjected to this extraction procedure.
We measured the concentration of methylFH4 by using the reference curve prepared with PGA in order to underestimate the true concentration of the methylFH4, because the objective of the procedure is to measure only stable folate. Only 5.2% of the methylFH4 added to the serum in a concentration range found in most normal sera was assayable after extraction, whereas 80 to 117% of the PGA added to serum was accounted for. The endogenous stable folate measured in serum from normal subjects ranged in concentration from 160 to 510 ng/L with a mean (±SEM) of 243 ± 40 ng/L. This stable folate component in serum approximated 2.8% of the total folate (4).
We determined the clearance of PGA from the plasma of two fasting normal subjects after administration of 15 izg/kg body weight. The total folate in whole serum was measured by the two-phase sequential noncompetitive radioassay (4)4 and stable folate was measured in the sera after extraction as described.
The results are shown in Figure  1 . For both subjects, there was an initial rapid decrease in the stable folate concentration, which represents the distribution of the PGA, followed by a slower clearance phase, representing metabolic turnover.
Within 1 to 2 mm after the injection of PGA, there was an increase in total serum folate that exceeded the sum of PGA assayed and the fasting preinjection concentration of total folate. This difference in peak concentration of total and stable folate probably represents displacement of hepatic (or other tissue) methylFH4
by the injected PGA as described by
Chanarin and McLean (13).
The difference between the concentration of total folate and PGA at each time period is the reduced labile methylFH4 in serum;
the rate of decrease of this pool, which is also shown in Figure 1 , is considerably slower than the clearance rate of either the PGA or total folate. We measured the urinary excretion of total folate and stable folate before and after the administration of PGA (Table 3 ). There was very little stable folate in the control urine of both subjects; therefore, the stable folate measured in the 2-h urine collection represents the excretion of the administered PGA, which was 2.3 and 7.9% of the administered dose. However, there was also a significant increase in the urinary excretion of reduced folate, some of which reflects exchange of the PGA with tissue methylFH4 (13) and some representing conversion of the administered PGA to methylFH4, which was then excreted.
DIscussion
This report describes a radiochemical method for measuring, selectively, PGA and other stable folate(s) in serum in which the reduced labile methylFH4 is the major component ' In this radioassay procedure the folate-binding protein prepared from milk msused; the assay does not distinguish PGA and methylFH4 because it is a sequential noncompetitive type of radiometric assay. Therefore, it measures total folate in serum. Fig. 1 . The plasma clearance of PGA (15 zg/kg body weight) administered intravenously to two normal fasting subjects x, total serum folate; #{149}. stable folate measured; A, reduced folate, calculated from the difference between the totaland stable folate at each time period (2) . This small component of stable serum folate is difficult to quantify by microbiologic methods because these procedures lack the specificity to separate these classes of naturally occurring folates. Though S. faecalis and L. casei are the organisms most widely used to differentiate these classes of folate because the former organism cannot utilize methylFH4 for growth (2) , both of these organisms will grow on virtually all other monoglutamate-folate derivatives. The previously described radioimmunoassay for PGA can also measure this small fraction of stable folate in serum (8) , but the difficulty of consistently obtaining high affinity antiserum to PGA has limited the value of this procedure.
This radiochemical method utilizes an extraction procedure in which methylFH4, the major component of serum folate, is denatured by peroxide oxidation and the remaining stable folate is measured by radioassay and compared with a PGA standard curve, with use of the folate binder from CML cells (10) . This folate binder has low affinity for methylFH4 so that, even if a small fraction of endogenous methylFH4 is not destroyed by the peroxide treatment, it will not contribute significantly to the value for stable folate. Using this method, we have been able to measure a small concentration of stable folate in normal sera, the identification and significance of which require further study. This method has, however, been used to measure selectively the urinary excretion and plasma clearance of PGA from the serum of two fasting normal subjects. By measuring separately the PGA and total folate in serum, we observed that the peak of total folate was greater than the sum of the PGA and circulating endogenous folate, indicating that there must have been a rapid release of additional folate from the tissues, and this was probably methylFH4.
The difference in the values of PGA and total folate represents reduced folate (again, methylFH4) and the plasma clearance of this folate was slower than the administered PGA. The re-entry of nascent methylFH4 synthesized from the administered PGA could decrease the rate of clearance of the reduced folate. However, there is also likely to be a basic difference in the cellular uptake of these folates, because Chanarin (14) also observed that methylFH4 was cleared more slowly from the plasma than was PGA after their separate administration.
In This radiochemical assay method, which selectively measures stable folate, can be used to study this minor but possibly metabolically significant fraction of serum folate. In combination with the radioassay to measure total folate, it can be a useful tool for studying the metabolic conversion of PGA into reduced folate and for estimating the hepatic (and other tissue) storage pools of methylFH4 by the displacement and urinary excretion of reduced folate. Such studies are now in progress in normal subjects and in patients with disturbances of folate and vitamin B12 metabolism. This work was supported by AM 16220 from the NIAMD, NIH.
